Merck's KEYNOTE-671 Trial Shows Promising Overall Survival Results in Resectable NSCLC

Merck's Phase 3 KEYNOTE-671 trial investigating KEYTRUDA as a perioperative treatment for resectable stage II, IIIA, or IIIB non-small cell lung cancer (NSCLC) has met its dual primary endpoint of overall survival (OS). The trial demonstrated a statistically significant and clinically meaningful improvement in OS when KEYTRUDA was used as neoadjuvant therapy followed by surgery and adjuvant therapy, compared to placebo plus chemotherapy. These results mark a significant milestone in the treatment of resectable NSCLC and offer potential extended survival for patients in earlier stages of the disease.